Tandem Diabetes Care (TNDM) Return on Capital Employed (2014 - 2026)

Tandem Diabetes Care's Return on Capital Employed history runs 13 years deep, the most recent figure standing at 10.89% for Q1 2026.

• Quarterly Return on Capital Employed rose 1626.0% year-over-year to 10.89% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 10.89% (up 1626.0% YoY) and the FY2025 annual result came in at 27.47%, down 1357.0% from the prior year.
• Return on Capital Employed was 10.89% for Q1 2026 at Tandem Diabetes Care, up from 29.48% in the prior quarter.
• Across five years, Return on Capital Employed topped out at 1.27% in Q1 2022 and bottomed at 31.5% in Q3 2025.
• A 5-year average of 19.64% and a median of 19.9% in 2024 frame the typical range for Return on Capital Employed.
• Annual changes were most pronounced in 2023 — Return on Capital Employed sank 2909 bps — and 2024, when it surged 1720 bps.
• Tandem Diabetes Care's Return on Capital Employed stood at 10.49% in 2022, then slumped by 196 bps to 31.05% in 2023, then surged by 55 bps to 13.85% in 2024, then sank by 113 bps to 29.48% in 2025, then jumped by 63 bps to 10.89% in 2026.
• Business Quant data shows TNDM's Return on Capital Employed at 10.89% in Q1 2026, 29.48% in Q4 2025, and 31.5% in Q3 2025.